This is a working overview of glucagon receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-10-30. Anything still debated is marked as such rather than presented as settled.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Other innovative efforts included their "MySpace Ted" campaign, which took advantage of the popularity of social networking, and the burgeoning user-submission marketing movement via their Vice President of Pizza contest. In 2023, as a promotional tie-in to the Teenage Mutant Ninja Turtles: Mutant Mayhem animated film, Pizza Hut began offering delivery to designated locations in the New York City subway.
=== Notch signaling === In 2015 and 2017, Garcia published articles in Science describing the first atomic-level visualizations of Notch signaling complexes. Garcia's group used directed evolution to strengthen low-affinity interactions between the receptor Notch1 and ligands Delta-like 4 (DLL4) and Jagged1 (Jag1) as a means of stabilizing the complexes for co-crystallization. Notch1-DLL4 and Notch1-Jag1 structures were determined by x-ray crystallography and revealed long, narrow binding interfaces assisted by multiple O-linked fucose and glucose modifications on Notch1. O-linked glycans are rarely observed at protein-protein interfaces, and their presence at the Notch-ligand interface explained how changes in glycosylation state influence Notch signaling activity. Garcia's 2017 publication also established that Notch-ligand interactions form catch bonds, and that Delta-like and Jagged ligands have different mechanical force thresholds for Notch receptor activation.
Both carboxamides and aldoximes can be dehydrated using aluminum chloride and sodium iodide in acetonitrile. Likewise, both classes can be dehydrated with oxalyl chloride and catalytic dimethyl sulfoxide in a reaction analogous to the Swern oxidation. Conversion to nitriles under catalysis by heptavalent rhenium species (perrhenic acid or trimethylsilyl perrhenate) is effective for both amides and aldoximes; the water formed can be removed by azeotropic distillation. The conversion of aldehydes to nitriles via aldoximes is a popular laboratory route. Aldehydes react readily with hydroxylamine salts, sometimes at temperatures as low as ambient, to give aldoximes. These can be dehydrated to nitriles by simple heating, although a wide range of reagents may assist with this, including triethylamine/sulfur dioxide, zeolites, or sulfuryl chloride. The related hydroxylamine-O-sulfonic acid reacts similarly.
== Production == Lucia Aniello, Paul W. Downs, and Jen Statsky developed the idea for Hacks on a road trip in 2015. The three worked together previously on Broad City, and Aniello and Downs are romantic partners. HBO Max ordered the pilot for Hacks, a single-camera comedy series, from co-creators Aniello, Downs, and Statsky in January 2020, and then picked it up for a 10-episode order in May 2020. The series is co-executive produced with Michael Schur (Fremulon), and David Miner and Morgan Sackett (3 Arts Entertainment). Hacks is produced by Universal Television. On February 8, 2021, Jean Smart and Hannah Einbinder were announced as the two lead cast members and Carl Clemons-Hopkins was announced as a main cast member. Additional recurring cast members were also announced: Kaitlin Olson, Christopher McDonald, co-creator Paul W. Downs, Mark Indelicato, Poppy Liu, Johnny Sibilly, Meg Stalter, and Rose Abdoo. The series premiered on May 13, 2021, with the release of episodes one and two.
Sources: en.wikipedia.org
== Research == Diphenoxylate and atropine have been studied in small trials as a treatment for fecal incontinence; it appears to be less efficacious and have more adverse effects when compared with loperamide or codeine.
These are Directive 2004/23/EC on standards of quality and safety for the sourcing and processing of human tissues which was adopted by the European Parliament in 2004 and a proposed Human Tissue-Engineered Products regulation. The latter was developed under the auspices of the European Commission DG Enterprise and presented in Brussels in 2004.
The best-known practitioner in this genre was the English taxidermist Walter Potter, whose most famous work was The Death and Burial of Cock Robin. Among his other scenes were "a rat's den being raided by the local police rats ... [a] village school ... featuring 48 little rabbits busy writing on tiny slates, while the Kittens' Tea Party displayed feline etiquette and a game of croquet." Apart from the simulations of human situations, he had also added examples of bizarrely deformed animals such as two-headed lambs and four-legged chickens. Potter's museum was so popular that an extension was built to the platform at Bramber railway station. Other Victorian taxidermists known for their iconic anthropomorphic taxidermy work are William Hart and his son Edward Hart. They gained recognition with their famous series of dioramas featuring boxing squirrels. Both William and Edward created multiple sets of these dioramas. One 4-piece set of boxing squirrel dioramas (circa 1850) sold at auction in 2013 for record prices. The four dioramas were created as a set (with each diorama portraying the squirrels at a different stage during their boxing match); however, the set was broken up and each was sold separately at the same auction. The set was one of a number they created over the years featuring boxing squirrels.
The 1958 Convention on the High Seas defined "high seas" to mean "all parts of the sea that are not included in the territorial sea or in the internal waters of a State" and where "no State may validly purport to subject any part of them to its sovereignty". Ships sailing the high seas are generally under the jurisdiction of their flag state (if there is one); however, when a ship is involved in certain criminal acts, such as piracy, any nation can exercise jurisdiction under the doctrine of universal jurisdiction regardless of maritime borders. As part of their air and maritime border control policies, most countries restrict or regulate the ability of foreign airlines and vessels to transport goods or passengers between seaports and airports in their jurisdiction, known as cabotage. Restrictions on maritime cabotage exist in most countries with territorial and internal waters to protect the domestic shipping industry from foreign competition, preserve domestically owned shipping infrastructure for national security, and ensure safety in congested territorial waters. For example, in America, the Jones Act provides for extremely strict restrictions on cabotage. Similarly, China does not permit foreign flagged vessels to conduct domestic transport or domestic transhipments without the prior approval of the Ministry of Transport. While Hong Kong and Macau maintain distinct internal cabotage regimes from the mainland, maritime cabotage between either territory and the mainland is considered domestic carriage and accordingly is off limits to foreign vessels.
=== Future Outlooks of DNA Legos === DNA Legos have promising applications in drug encapsulation and intracellular delivery. DNA nanoparticles are created to have reactive groups with two pegs in a singular direction and two holes in another . This structure allows the bricks to connect and create various shapes. The shapes of the bricks can become complex to encapsulate various drug molecules. These shapes have been applied in an attempt to improve cancer immunotherapies. For example, DNA Legos have been formed into a star shape with sticky ends to encapsulate doxorubicin. When mixed in solution the sticky ends rapidly join together forming an icosahedron shaped brick with the anticancer drug inside of this structure. Another study investigated cellular uptake of spherical nucleic acid bricks (SNAs). Through SNA and dendritic cell interactions, tumor cells are efficiently killed as the spherical brick shape allows for tunable subcellular trafficking and peptide retention. Thus, creating various shaped DNA brick nanoparticles may improve efficacy of immunotherapies by encapsulating drug cargo improving cell uptake. Before DNA Legos can have clinical applicability as a nanoparticle, they must be stabilized to ensure proper drug release. Previously, RNA bricks have been locked in place by magnesium. Utilizing magnesium to set the shape of RNA bricks via kissing interactions allows for easy tunability of structures. This idea is easily translatable to DNA thus creating a mechanism in which DNA Legos can be stabilized for clinical use.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.